Skip to content

Report from the Annual General Meeting of Promore Pharma AB held on 27 May 2021

Promore Pharma AB, reg. no. 556639-6809, held its AGM on Thursday, 27 May 2021. The main resolutions passed at the meeting were as follows.

More detailed information about the contents of the resolutions may be obtained from the complete notice of the AGM and the complete proposals. The notice and complete proposals are available on the company’s website,

Adoption of balance sheets and profit and loss accounts
It was resolved at the meeting to adopt the profit and loss account and balance sheet, as well as the consolidated profit and loss account and consolidated balance sheet for the financial year 2020.

Allocation of result
It was decided that the unappropriated profit of SEK 30,542,480 will be carried forward, in accordance with the Board’s proposal.

Discharge from liability
The meeting discharged the directors and the CEO from liability for the financial year 2020.

Directors and auditors
Marianne Dicander Alexandersson, Satyendra Kumar, Göran Linder, Göran Pettersson, and Kerstin Valinder Strinnholm were re-elected and Hans-Peter Ostler was elected as directors. Göran Pettersson was re-elected Chairman of the Board.

The registered audit company Finnhammars Revisionsbyrå AB was re-elected as auditor.

It was decided that the total fees to the directors for the period until the end of the next AGM will amount to SEK 1,000,000, whereof SEK 250,000 to the Chairman of the Board and SEK 150,000 each to the other directors.

Fees will be paid to the auditor on current account.

Board authorisation
It was decided to authorise the Board to, with or without deviation from the shareholders’ preferential rights, for the period to the next annual general meeting and on one or several occasions, issue shares, convertibles and warrants, in accordance with the Board’s proposal.

The number of shares that the Board shall be entitled to issue, the number of shares that convertibles may entitle to and the number of shares that may be subscribed for on account of warrants, shall totally amount to no more than 7,285,672 new shares, corresponding to a dilution of approximately 20 per cent.

Amendment of the articles of association
It was decided to amend the articles of association, in accordance with the Board’s proposal.